Clinical Trial Search

Primary: Number of Discrete Biotinylated RBC Densities (up to 5 Discrete Densities) That Can be Accurately Measured by Flow Cytometry, i.e., Without Overlap. — 5; 5 flow…

Primary: Percentage of Participants With Both Clinical Response at Week 10 and Clinical Remission at Week 54, as Determined by the Mayo Clinic Score (MCS) — 18.6; 19.7 percentage…

Primary: Change in Age-Adjusted Scores at Week Six From Baseline in the Attention Task of the CogState Battery — -0.16; 0.14 Z Score

Primary: Number of Oxycodone Tablets Used Day 1 — 1.0; 1.0 Oxycodone Tablets — p=.87

Primary: Vitamin D Status — 81.6; 5.6 Percentage of participants in study arm

Primary: Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day — -2.72; -1.62; -0.89; -1.52 episodes per day — p=0.0845

Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants

Primary: Rates of Grade 2 and Higher Alanine Aminotransferase (ALT) Elevations — 24; 30 Participants

Primary: Diagnostic Accuracy of SHAPE Liver Pressure Estimates (in dB) for Diagnosing Portal Hypertension With Catheter Pressure Measurements (in mmHg) as the Reference Standard…

Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months

Primary: Change in Brain Nicotinamide Adenine Dinucleotide Metabolites NAD+/NADH — -0.79 ratio

Primary: Progression-free Survival (PFS) as Per RECIST v 1.1 Using Central Assessment - Number of Participants With Progression or Death — 62; 32; 3; 1 Participants

Primary: Total COPD Exacerbation Rate — 1.00; 0.86; 0.89 Exacerbations per participant year

Primary: Efficacy of Combined Treatment With Deferasirox and Deferoxamine Over 12 Months — -6.2 mg/g

Primary: Objective Response Rate (ORR) — 5.3 Percent of participants